Beijing Huanuotai Biopharmaceutical Technology

Huanuotai Bio is a clinical-stage Chinese biotechnology company specializing in the development of innovative vaccines and proprietary novel adjuvant systems. The company leverages its integrated technology platforms, including a high-efficiency recombinant protein expression system and a diverse library of novel adjuvants, to create next-generation immunotherapies for infectious diseases. Its lead clinical programs include a recombinant Respiratory Syncytial Virus (RSV) vaccine and a recombinant Herpes Zoster (Shingles) vaccine, both designed to offer improved safety and efficacy profiles compared to existing options. Headquartered in Beijing with manufacturing facilities in Taizhou, Huanuotai Bio is positioned to address significant global public health challenges through its end-to-end vaccine R&D capabilities.